Opendata, web and dolomites

SkinXCare

Integral cell-biology platform for the development of the first effective treatment of radiodermatitis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SkinXCare" data sheet

The following table provides information about the project.

Coordinator
INNOVATIVEHEALTH GROUP SL 

Organization address
address: CALLE HERMOSILLA NUMERO 149 1B
city: MADRID
postcode: 28028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.innohealthgroup.com/simhealth/skinxcare
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INNOVATIVEHEALTH GROUP SL ES (MADRID) coordinator 50˙000.00

Map

 Project objective

InnoHealth Group is a private company born with the mission of offering novel dermatological formulations, with a major focus on the rational development (scientific-based approach) of new and more effective therapeutic solutions to dermatological diseases. Our vision is to become a leading player of the therapeutic dermatology and skin care markets segments, something that will be enabled thanks to our patented cell biology platform for the development of novel products. Our platform is the only one in the market that integrates novel bioinformatic tools based on cellular proteomic/kinome data (SkinSim and INCOS) and in vitro assays (SimDerma) for the rational design and development of new dermatological formulations. The combination of these tools in the platform allows identifying the molecular/celular targets involved in skin diseases and the combinations of active ingredients/compounds with the highest synergistic activity in these targets for disease treatment. This makes our platform a key enabling technology for the development of new dermatological products, especially in treatment of skin diseases without a known efficient therapeutic solution because of the complexity in the cellular and biochemical damages underlying such diseases. In the SkinXCare project we seek demonstrating the potential of our platform by its use in the development of the first effective treatment of radiodermatitis, a severe skin condition that affects cancer patients undergoing radiotherapy and still remains an unmet clinical condition. Thanks to the uniqueness of the solution proposed in the SkinXCare project, we seek becoming a leading player of therapeutic dermatology market. This market segment was valued at €24.5 billion on 2015 and is predicted to grow at a CAGR of 6.7% until 2025, key figures that further sustain the SkinXCare business opportunity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SKINXCARE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SKINXCARE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More